Clinical trials: Immune Checkpoint Blockade
Lung Cancer, Nonsmall Cell
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
This is a prospective, randomized, single-site, open-label Phase II trial of neoadjuvant pembrolizumab (3 cycles) followed by surgery, versus concomitant neoadjuvant pembrolizumab with platinum doublet chemotherapy (3 cycles)…
- Trial name
- NCT04638582
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- Canada
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre